Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schruers, K.
Right arrow Articles by Griez, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schruers, K.
Right arrow Articles by Griez, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 18, No. 4, 553-558 (2004)
DOI: 10.1177/0269881104047283

The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder

Koen Schruers

Department of Psychiatry and Neuropsychology, Research Institute Brain and Behaviour, Maastricht University, Maastricht, The Netherlands, koen.schruers{at}pn.unimaas.nl

Eric Griez

Department of Psychiatry and Neuropsychology, Research Institute Brain and Behaviour, Maastricht University, Maastricht, The Netherlands

Antidepressants that inhibit the reuptake of serotonin (5-HT) are particularly effective in the treatment of panic disorder. Evidence suggests that increased 5-HT availability is important for the anti-panic effect of serotonergic drugs and in maintaining the response to selective serotonin reuptake inhibitors (SSRIs). Tianeptine is an antidepressant with 5-HT reuptake enhancing properties (i.e. the opposite pharmacological profile to that of SSRIs). Therefore, no effect would be expected in panic disorder. The aim of the present study was to compare the effect of tianeptine with that of paroxetine, a selective 5-HT reuptake inhibitor with demonstrated efficacy in panic disorder, on the vulnerability to a laboratory panic challenge in panic disorder patients. Twenty panic disorder patients were treated with either tianeptine or paroxetine for a period of 6 weeks, in a randomized, double-blind, separate group design. The reaction to a 35% CO2 panic challenge was assessed at baseline and after treatment. Improvement on several clinical scales was also monitored. Tianeptine, as well as paroxetine, showed a significant reduction in vulnerability to the 35% CO2 panic challenge. In spite of their opposite influence on 5-HT uptake, both tianeptine and paroxetine appeared to reduce the reaction to the panic challenge. These results raise questions about the necessity of 5-HT uptake for the therapeutic efficacy of anti-panic drugs.

Key Words: carbon dioxide challenge • panic disorder • paroxetine • serotonin • tianeptine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
J. E. Bailey, A. Kendrick, A. Diaper, J. P. Potokar, and D. J. Nutt
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
J Psychopharmacol, January 1, 2007; 21(1): 42 - 49.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
S. Z. Poma, S. Milleri, L. Squassante, G. Nucci, M. Bani, G. I. Perini, and E. Merlo-Pich
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects
J Psychopharmacol, September 1, 2005; 19(5): 494 - 503.
[Abstract] [PDF]